Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial. by Butler, Javed et al.
Thomas Jefferson University
Jefferson Digital Commons
Department of Medicine Faculty Papers Department of Medicine
9-1-2017
Efficacy and Safety of Spironolactone in Acute
Heart Failure: The ATHENA-HF Randomized
Clinical Trial.
Javed Butler
Stony Brook University
Kevin J. Anstrom
Duke University
G. Michael Felker
Duke University
Michael M. Givertz
Brigham and Women’s Hospital, Harvard Medical School
Andreas P Kalogeropoulos
Emory University
See next page for additional authors
Let us know how access to this document benefits you
Follow this and additional works at: https://jdc.jefferson.edu/medfp
Part of the Cardiology Commons
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
Recommended Citation
Butler, Javed; Anstrom, Kevin J.; Felker, G. Michael; Givertz, Michael M.; Kalogeropoulos, Andreas
P; Konstam, Marvin A.; Mann, Douglas L.; Margulies, Kenneth B.; McNulty, Steven E; Mentz,
Robert J.; Redfield, Margaret M.; Tang, W.H. Wilson; Whellan, David J.; Shah, Monica; Desvigne-
Nickens, Patrice; Hernandez, Adrian F.; and Braunwald, Eugene, "Efficacy and Safety of
Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial." (2017).
Department of Medicine Faculty Papers. Paper 222.
https://jdc.jefferson.edu/medfp/222
Authors
Javed Butler, Kevin J. Anstrom, G. Michael Felker, Michael M. Givertz, Andreas P Kalogeropoulos, Marvin A.
Konstam, Douglas L. Mann, Kenneth B. Margulies, Steven E McNulty, Robert J. Mentz, Margaret M.
Redfield, W.H. Wilson Tang, David J. Whellan, Monica Shah, Patrice Desvigne-Nickens, Adrian F.
Hernandez, and Eugene Braunwald
This article is available at Jefferson Digital Commons: https://jdc.jefferson.edu/medfp/222
Efficacy and Safety of Spironolactone in Acute Heart Failure: 
The ATHENA-HF Randomized Clinical Trial
Javed Butler1, Kevin J. Anstrom2, G. Michael Felker3, Michael M. Givertz4, Andreas P. 
Kalogeropoulos5, Marvin A. Konstam6, Douglas L. Mann7, Kenneth B. Margulies8, Steven 
E. McNulty2, Robert J. Mentz3, Margaret M. Redfield9, W H Wilson Tang10, David J. 
Whellan11, Monica Shah12, Patrice Desvigne-Nickens13, Adrian F. Hernandez3, and Eugene 
Braunwald4 on behalf of the National Heart Lung and Blood Institute Heart Failure Clinical 
Research Network
1Department of Medicine, Stony Brook University, Stony Brook, New York 2Duke Clinical 
Research Institute, Duke University, Durham, North Caroline 3Department of Medicine, Duke 
University, Durham, North Carolina 4Department of Medicine, Brigham and Women’s Hospital, 
Harvard Medical School, Boston, Massachusetts 5Department of Medicine, Emory University, 
Atlanta, Georgia 6The CardioVascular Center, Tufts Medical Center, Boston, MA 7Department of 
Medicine, Washington University, St. Louis, Missouri 8Department of Medicine, University of 
Pennsylvania, Philadelphia, Pennsylvania 9Department of Cardiovascular Diseases, Mayo Clinic, 
Minnesota 10Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 
11Department of Medicine, Thomas Jefferson University Philadelphia, Pennsylvania 12National 
Center for Advancing Translational Sciences, National Institutes of Health, Baltimore, Maryland 
13Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Baltimore, 
Maryland
Abstract
Importance—Persistent congestion is associated with worse outcomes in acute heart failure 
(AHF). Mineralocorticoid receptor antagonists at high doses may relieve congestion, overcome 
diuretic resistance, and mitigate the effects of adverse neurohormonal activation in AHF.
Objective—To assess the impact of high dose spironolactone in addition to usual care on N-
terminal pro-B-type natriuretic peptide (NTproBNP) levels compared to usual care alone.
Design—Double blind, placebo (or low dose)-controlled, multicenter, randomized clinical trial
Setting—Twenty-two acute care hospitals in the Unites States
Address correspondence to: Javed Butler, MD, MPH, Cardiology Division, Stony Brook University, T-16, Room 080, Stony Brook, 
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Participants—Patients with AHF and NTproBNP level of ≥1000 pg/mL or B-type natriuretic 
peptide ≥250 pg/mL regardless of ejection fraction, previously receiving no or low-dose (12.5 or 
25 mg daily) spironolactone
Intervention—High dose spironolactone (100 mg) vs. placebo or 25 mg spironolactone (usual 
care) daily for 96 hours
Main Outcomes Measures—The primary endpoint was change in NTproBNP levels from 
baseline to 96 hours. Secondary endpoints included clinical congestion score, dyspnea assessment, 
net urine output, and net weight change. Safety endpoints included hyperkalemia and changes in 
renal function.
Results—A total of 360 patients were randomized (median age 65 years, 36% women, 65% 
Caucasian, and median left ventricular ejection fraction of 34%. Baseline median NTproBNP 
levels were 4601 (2697, 9596) pg/ml in the high-dose spironolactone group and 3753 (1968, 7633) 
pg/ml in the usual care group. There was no significant difference in the log NTproBNP reduction 
between the two groups (−0.55 [−0.92, −0.18] with high-dose spironolactone and −0.49 [−0.98, 
−0.14] with usual care, P=0.57). None of the secondary endpoint or day-30 all-cause mortality or 
heart failure hospitalization rate differed between the two groups. The changes in serum potassium 
and estimated glomerular filtration rate at 24, 48, 72, and 96 hr. were similar between the two 
groups.
Conclusion and Relevance—Addition of high dose spironolactone to usual care in patients 
with AHF for 96 hours was well tolerated but did not improve either the primary or any of the 
secondary efficacy endpoints.
Keywords
Acute heart failure; aldosterone; heart failure; hospitalization; mineralocorticoid receptor 
antagonist; natriuretic peptide; spironolactone
Acute heart failure (AHF) accounts for over a million hospitalizations in the United States 
annually.1 Hospitalizations for HF are associated with a mortality or readmission risk of 
~30% at 60-days and ~50% by 6-month post discharge.2, 3 The already activated renin-
angiotensin-aldosterone-system (RAAS) in chronic heart failure may be further accentuated 
in AHF.4 The use of intravenous loop diuretics intensifies secondary hyperaldosteronism in 
these patients.5 Beyond myocardial and vascular adverse effects, hyperaldosteronism 
directly contributes to diuretic resistance in AHF.6 Elevated aldosterone levels in AHF are 
associated with increased risk of cardiovascular mortality and HF readmission.7
The role of low dose mineralocorticoid receptors antagonists (MRA) therapy as a 
neurohormonal antagonist is well established for the treatment of chronic heart failure and 
reduced ejection fraction. However, the role of high dose MRA therapy in AHF remains 
uncertain. Several studies have shown that mineralocorticoid receptors antagonists (MRA) at 
high doses result in significant natriuresis and help overcome diuretic resistance.8, 9 
However, there have been concerns regarding hyperkalemia and renal failure with MRA use 
especially with high doses.10 A single-center, single-blind, non-randomized, trial suggested 
benefit with high dose MRA therapy in AHF, including lower natriuretic peptide levels, less 
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congestion, better renal function, and less need for intravenous diuretic.11 Accordingly, we 
performed the Aldosterone Targeted NeuroHormonal CombinEd with Natriuresis TherApy 
in Heart Failure (ATHENA-HF) trial to test the hypothesis that high dose spironolactone use 
in patients with AHF will have a beneficial impact in patients with AHF.
METHODS
Study Oversight
The ATHENA-HF trial was sponsored by the National Heart, Lung, and Blood Institute and 
conducted by the Heart Failure Clinical Research Network. The protocol was approved by 
the network’s protocol review committee and monitored by the network’s data and safety 
monitoring board. The ethics committee at each participating site approved the trial. Data 
collection, management, and analysis were performed at the network’s coordinating center 
at Duke Clinical Research Institute. All authors reviewed and approved the manuscript and 
assume full responsibility for the accuracy and completeness of the data and for the fidelity 
of this report to the study protocol, which is available with the full text of this article.
Study Patients
The eligibility criteria for the ATHENA-HF trial included a clinical diagnosis of heart failure 
with at least one sign and one symptoms of AHF and with an NT-proBNP level of ≥1000 
pg/mL or BNP ≥250 pg/mL, regardless of ejection fraction, measured within 24 hours of 
randomization. Patients were eligible if they were either (1) receiving no spironolactone or 
(2) receiving low-dose spironolactone (12.5 or 25 mg per day) at home prior to admission. 
Patients were also required to have serum potassium concentration ≤5.0mmol/L, estimated 
glomerular filtration rate (eGFR) ≥30 mL/min/1.73m2 and systolic blood pressure >90 
mmHg. Patients receiving eplerenone were excluded since in an acute setting it may not be 
easily known if the patient had previously been intolerant to spironolactone. Patients already 
taking more than 25 mg of spironolactone were excluded.
Study Design
Detailed study design for the ATHENA-HF trial has been described previously.12 Briefly, 
this was a randomized, double blind, placebo controlled trial assessing the impact of high 
dose spironolactone in addition to usual care vs. usual care on N-terminal pro-B-type 
natriuretic peptide (NT-proBNP) levels at 96 hours among patients hospitalized for AHF. 
The study intervention was initiated within 24 hours of the first dose of intravenous 
diuretics. Patients not on spironolactone were randomized to 100 mg spironolactone or 
placebo. Those on low dose spironolactone prior to admission were randomized to 100 mg 
or 25 mg per day in the usual care alone arm; placebo was not given to these patients to 
avoid ethical concerns with discontinuing chronic stable therapy. Randomization was 
double-blind for both comparator strata and was not stratified according to previous low-
dose spironolactone. All other medications, including diuretics, were left at the discretion of 
the treating physician. The study drug was discontinued after 96 hours and further MRA use 
was left to the treating physician’s discretion. Data on left ventricular ejection fraction 
measured within 6 months prior to randomization were collected; when unavailable, it was 
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assessed during hospitalization. Algorithms were suggested for the management of 
worsening creatinine and hyperkalemia during the blinded period.
Study Endpoints
The primary endpoint was the proportional change in the log NT-proBNP levels from 
randomization to 96 hours (or at discharge if discharge was earlier than 96 hours). Multiple 
secondary endpoints from randomization to 96 hours were assessed. These included: a) 
clinical congestion score, calculated by summing the individual scores for orthopnea, jugular 
venous distension, and pedal edema on a standardized 4-point scale ranging from 0 to 3;13 b) 
dyspnea relief, measured by a Likert scale (ranging from 1=markedly improved to 7= 
markedly worse) and by the Visual Analog Scale (ranging from 0 to 100, with higher values 
indicating better status); c) cumulative net urine output on a daily basis for up to 96 h; d) net 
weight change from baseline to 96 h or discharge (whichever came first); e) furosemide 
equivalents of loop diuretic dose at discharge, and f) development of in-hospital worsening 
HF, with signs and symptoms requiring additional therapy. Exploratory endpoints included a 
day-30 post randomization composite of all-cause mortality, all-cause readmission, or 
outpatient worsening heart failure (heart failure related readmission or emergency 
department visit or need for outpatient intravenous diuretics). Participants were also 
contacted by telephone at 60±3 days to assess vital status. Safety endpoints included change 
in serum creatinine, estimated glomerular filtration rate, and incidence of moderate 
(>5.5mmol/L) and severe hyperkalemia (>6.0mmol/L) during the 96-hour treatment period.
Statistical Analysis
It was anticipated that 25% of subjects enrolled would be on low-dose MRA at 
randomization. Assuming a 20% further reduction in NT-proBNP from randomization in the 
MRA group compared to placebo and a 10% reduction in those on low-dose MRA at 
baseline, yielded an overall benefit of 17.5% for the study population. With a 1:1 
randomization and a two-sided type I error rate of 0.05, a total of 360 subjects provided 
approximately 85% power. Randomization was conducted using a permuted block design 
with stratification based on site and MRA usage at enrollment. The primary analysis used a 
linear regression model with an indicator variable for treatment assignment, an indicator for 
MRA use prior to admission, and the log of the baseline NT-proBNP level. We opted to 
analyze log-transformed NT-proBNP levels because of better distributional properties and 
therefore improvements in the underlying assumptions of the statistical models involving 
NT-proBNP. Missing values of the 96-hour NT-proBNP levels (22 in usual care and 23 in 
high dose spironolactone group) were imputed using a multiple imputation algorithm. In a 
sensitivity analysis, values missing due to death were imputed to the worst possible value.14 
This analysis accounted for low-dose MRA prior to admission using a stratified version of 
the Wilcoxon-Mann-Whitney test. For binary outcomes, chi-square tests and Fisher’s exact 
test were used for unadjusted comparisons. Unadjusted time-to-event comparisons were 
conducted using Kaplan-Meier survival estimates and log-rank tests. Cox proportional 
hazards regression models were used to estimate hazard ratios (HR) and 95% confidence 
intervals (CI). Four pre-specified subgroup analyses were conducted including baseline low 
dose MRA use, gender, ejection fraction (greater than versus less than or equal to 45%), and 
age (greater than versus equal to or less than 65 years). Data are presented as median 
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(interquartile range [IQR]). For primary and secondary end points, a P value less than .05 
was considered significant. For subgroup analyses, a treatment by subgroup interaction p 
less than .01 was considered significant. All analyses were conducted with the use of SAS 
statistical software version 9.2.
RESULTS
Study Patients
From December 2014 to April 2016, 360 patients were enrolled from 22 sites for an 
enrollment rate of ~1 patient/site/month. A total of 182 patients were randomized to high-
dose spironolactone plus usual care and 178 to usual care alone (placebo N=132 or 
continued low dose spironolactone N=46) Figure 1. Baseline characteristics of the patient 
population are shown in Table 1. Note that the use of medication at baseline reflects those 
that the patients were given at randomization, which was within 24 hours of first dose of I.V. 
diuretics. The number of patients on spironolactone was lower at randomization than pre-
admission as home medications were discontinued at admission for some patients. The 
median age was 65 years, 36% were females, and 56% were White. Median ejection fraction 
was 34%; 93 patients (26%) had ejection fraction >45%. Median systolic blood pressure was 
122 mmHg, heart rate was 79 bpm, serum potassium concentration was 4.0 meq/L, serum 
creatinine was 1.2 mg/dl, and estimated glomerular filtration rate (eGFR) was 56 ml/min.
Efficacy
Baseline median (interquartile range) NTproBNP levels were 4601 pg/ml (IQR, 2697, 9596 
pg/ml) in the spironolactone and 3753 pg/ml (IQR, 1968–7633 pg/ml) in the usual care 
group. All randomized patients completed the study. There was no significant difference in 
the primary endpoint between the two groups (log NTproBNP change −0.55; −0.92, −0.18 
in the spironolactone and −0.49; −0.98, −0.14 in the usual care arm; P=0.57). Changes in log 
NT-proBNP were similar in analyses using only complete cases, i.e. without imputation 
(−0.56; −0.96, −0.19 in the spironolactone and −0.50; −0.99, −0.14 in the usual care arm; 
P=0.57). None of the secondary endpoint including dyspnea score (Likert and Visual Analog 
scales), clinical congestion score, net urine output, weight change, requirement for loop 
diuretics, and in hospital worsening heart failure were different between the two groups 
(Table 2). Of note, NT-proBNP levels in Table 1 (on-site qualification values before 
randomization) vs. Table 2 (core lab values before treatment initiation) were drawn at 
different times and patients in the two groups may have had different treatments and 
responses to them in the interim. At discharge, mean furosemide dose (in IV furosemide 
equivalents) was 89.5 mg in the spironolactone vs. 98.0 mg in the placebo group. In the 
spironolactone group, 26 patients (14%) were discharged on spironolactone (1 on 50 mg, 17 
on 25 mg, and 8 on 12.5 mg) vs. 35 (20%) in the placebo group (2 on 50 mg, 25 on 25 mg, 
and 8 on 12.5 mg). At 96 h, thiazide use was 3% in the usual care and 4% in the high-dose 
spironolactone group. Median time from randomization to discharge was 4 (2, 7) days in 
both groups. Two and 7 patients in the usual care and, 2 and 5 in high-dose spironolactone 
group died during the index hospitalization and through day 30 respectively. There was no 
difference in time to first heart failure readmission, emergency visit, or death between the 
two groups (adjusted HR 1.22, 95%CI 0.68, 2.19; P=0.50; Figure 2). There was no 
Butler et al. Page 5
JAMA Cardiol. Author manuscript; available in PMC 2017 November 07.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
difference in all-cause mortality at day-60. There was no difference in day-30 MRA use 
between the two groups (36% usual care alone vs. 31% high-dose spironolactone group, 
p=0.24).
Safety
High dose spironolactone was well tolerated. The changes in serum potassium, creatinine, 
and estimated glomerular filtration rate from baseline to 24, 48, 72, and 96 hr is shown in 
Table 3. Only one patient in the usual care group and none in the high dose spironolactone 
group experienced serum potassium levels between 5.5–5.9 mmol/L and no one had 
potassium concentration > 6.0 mmol/L during the 96 hours of study treatment. Serious 
adverse events by day-30 were reported in 84 (47%) patients in the usual care group and 79 
(43%) patients in the high-dose spironolactone group (P=0.47). Worsening renal function, 
defined as an increase of 0.3 mg/dl in creatinine from baseline through 96 hours, occurred in 
51/182 (28%) in the high-dose spironolactone group and 57/178 (32%) in the usual care 
group (P=0.42). No differences between groups were observed in terms of changes in heart 
rate or blood pressure levels during treatment.
Sub-Group Analysis
No differences were observed in the primary endpoint between patients randomized to high 
dose spironolactone or usual care stratified by age, gender, or use of low dose spironolactone 
at baseline (Supplementary Figure). The change in log NTproBNP levels at 96 hours or at 
earlier discharge in the spironolactone and usual care groups respectively among patients 
with ejection fraction ≤45%was −0.55 (−0.92, −0.19) and −0.54 (−0.99, −0.15), and in those 
with ejection fraction >45% was −0.53 (−1.03, −0.14) and −0.42 (−0.64, −0.03) (interaction 
P=0.078). The results were similar when only complete cases were analyzed without 
imputation (ejection fraction ≤45%: spironolactone −0.56 [−0.92, −0.20] vs. usual care 
−0.56 (−1.01, −0.15]; ejection fraction >45%: spironolactone −0.57 [−1.11, −0.19] vs. usual 
care −0.43 [−0.64, −0.09]).
DISCUSSION
In this study, which represents the first double blind multicenter trial assessing the efficacy 
and safety of high dose spironolactone in AHF, there was no benefit or risk seen with active 
intervention over usual care on either the primary or any of the secondary endpoints. These 
include changes in NTproBNP levels, urine output, weight changes, symptoms or congestion 
score. These results are in contrast to some of the earlier mechanistic and clinical data that 
suggested increased urine output and less congestion with the use of high dose MRA 
therapy. High dose spironolactone therapy was well tolerated without any significant risk of 
hyperkalemia or worsening renal function in the population of patients who met the 
eligibility criteria for the ATHENA-HF trial.
The eligibility criteria for ATHENA-HF were chosen to represent a generalizable AHF 
population. The inclusion criteria of glomerular filtration rate >30 ml/min resulted in a 
cohort with a median rate of 56 ml/min. Both study groups had significant diuresis and lost 
over 6 lbs. of weight in the first 96 hr. or by earlier discharge. It is possible that targeting 
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diuretic resistant patients with lower glomerular filtration rate may lead to better results with 
high dose spironolactone. No difference was seen in the use of diuretic doses between the 
two study arms, so it does not appear that high-dose spironolactone led to a selective early 
reduction in loop diuretic doses in the active intervention. No differences were noted 
between patients who were MRA naïve vs. those on low dose spironolactone at baseline and 
hence the neutral results cannot be attributed to chronic MRA use in a proportion of patients. 
Is it possibility that 100 mg spironolactone is not a high enough dose and that higher doses 
are needed. This possibility is intriguing considering that previous smaller heart failure 
studies have used up to 200 mg of spironolactone similar to the doses used in cirrhosis.8 
This approach may be explored in the future considering the safety of 100 mg 
spironolactone in the ATHENA-HF trial. Emerging data with novel potassium binders 
reducing the risk of hyperkalemia may further facilitate such a study.10 Spironolactone is a 
prodrug that is converted to active metabolite canrenone, which is responsible for its 
mineralocorticoid effects.15 Considering the short duration of AHF hospitalizations in the 
United States averaging at 4–5 days,16 using intravenous canrenoate with faster onset of 
action may be more beneficial. Similarly, new non-steroidal MRA finerenone that does not 
require conversion to an active metabolite may be more useful in the AHF setting.17
There were no safety concerns raised by the use of high dose spironolactone in this trial. 
There is a substantial risk of hyperkalemia even with lower doses of spironolactone in 
patients with chronic heart failure.10 With the active changes in glomerular filtration rate and 
blood pressure commonly encountered in the setting of AHF, the risk of hyperkalemia with 
high dose spironolactone is of concern. However, our study confirms that in the hospital 
setting high dose spironolactone use is safe in patients with relatively preserved renal 
function and with the implementation of other precautions and protocols such as those used 
in this trial. These data are encouraging for future research with either higher dose MRA in 
AHF than used in ATHENA HF, or in patients with worse renal function and diuretic 
resistance.
There were no differences in the efficacy or safety of high dose spironolactone therapy in 
any of the pre-specified sub-groups based on age, gender, or previous use of MRA. 
Interesting, while no differences were seen among patients with ejection fraction ≤45%, in 
patients with ejection fraction >45%, spironolactone intervention led to a numerically higher 
reduction in log NTproBNP levels with a trend toward a significant treatment-by-subgroup 
interaction. Though the trial was not powered to assess differences among patients with 
reduced vs. preserved ejection fraction, these data are intriguing as the Renal Optimization 
Strategies Evaluation (ROSE) trial also showed a differential trend with low dose dopamine 
use in AHF patients between those with preserved vs. reduced ejection fraction.18 While it is 
a standard for chronic heart failure trials to study patients with reduced and preserved 
ejection fraction separately, a number of recent AHF trials have included patients regardless 
of ejection fraction. The results of the ATHENA-HF trials provide data to encourage further 
study of the differences between these two patient populations in the AHF setting.
Our study has several limitations. First, the duration of the treatment (96 h or until discharge, 
whichever came first) was relatively short. Considering that spironolactone may take few 
days to convert to its active metabolites, especially in the presence of hepatic congestion, we 
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cannot exclude the possibility that longer treatment duration may have shown differences 
between the two groups. Second, data on the primary endpoint (change in NT-proBNP 
levels) were missing for approximately 12% of the study population. However, imputed, 
worst-possible-value, and raw analyses all pointed to a neutral effect of spironolactone on 
NT-proBNP levels. Third, in order for the trial to represent better the real-world population 
with AHF, we included a number of patients (25%) already receiving low-dose MRA at 
home and this may have influenced the treatment effect, thus contributing towards the 
neutral results. Of note, there was no differential effect of high-dose spironolactone between 
low-dose and no baseline MRA strata. Fourth, our study was not powered to explore 
differences according to ejection fraction. Finally, we excluded patients with glomerular 
filtration rate ≤30 ml/min and therefore our results, especially regarding safety, cannot be 
extrapolated to these patients.
In conclusion, high dose spironolactone in AHF was not associated with improvement in 
either the primary or the secondary outcomes in the ATHENA-HF trial. This intervention 
was safe and well tolerated. Future research should study higher doses and patients with 
diuretic resistance and should explore differences between patients with preserved vs. 
reduced ejection fraction.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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KEY POINTS
Question
Does addition of high-dose spironolactone in patients with acute heart failure lower 
natriuretic peptide levels and improve outcomes better than usual care?
Findings
High-dose spironolactone use in acute heart failure was not associated with improvement 
in natriuretic peptide levels, symptoms, congestion, urine output, weight loss, or clinical 
outcomes than usual care group.
Meaning
Routine use of high-dose spironolactone in acute heart failure is not recommended. 
Further studies targeting specifically diuretic resistant patients with high-dose 
spironolactone are needed.
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Figure 1. 
CONSORT Flow Diagram
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Figure 2. Time to first heart failure re-hospitalization, emergency room visit, or death
There were no significant differences noted in the post-discharge outcomes among patients 
randomized to the usual care alone vs. the high-dose spironolactone group
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Table 1
Baseline Patient Characteristics
Baseline Characteristics Usual care alone (N=178) High-dose spironolactone (N=182)
Demographics
Age (yr.) 65 (54, 74) 65 (57, 76)
Female - no. (%) 64 (36) 65 (36)
Race
 White - no. (%) 99 (56) 101 (55)
 Black - no. (%) 77 (43) 74 (41)
 Others - no. (%) 2 (1) 7 (4)
Hispanic or Latino - no. (%) 6 (3) 2 (1)
Past Medical History – N (%)
 Myocardial Infarction 52 (30) 51 (28)
 Hypertension 142 (81) 159 (87)
 Stroke 26 (15) 29 (16)
 Atrial fibrillation 84 (48) 88 (50)
 Chronic Lung Disease 43 (24) 39 (21)
 Diabetes Mellitus 74 (42) 72 (40)
 Chronic Kidney Disease 54 (31) 43 (24)
 Obstructive Sleep Apnea 41 (25) 41 (25)
 Current smoker 25 (15) 31 (17)
Baseline Treatment - N (%)a
 Angiotensin converting enzyme inhibitor or angiotensin receptor 
blocker
112 (63) 105 (58)
 Beta blockers 132 (74) 135 (74)
 Mineralocorticoid receptor antagonists 21 (12) 19 (11)
 Loop diuretics 169 (95) 177 (97)
  Furosemide equivalent dose (median, mg) 80 (40, 160) 80 (40, 160)
  Furosemide equivalent dose (mean, mg) 118.8 ± 94.4 122.5 ± 113.8
 Thiazide diuretics 3 (2) 3 (2)
 Digoxin 19 (11) 15 (8)
 Hydralazine 47 (26) 44 (24)
 Long-acting Nitrates 33 (19) 35 (19)
 Calcium channel blockers 23 (13) 36 (20)
 Statin 101 (57) 104 (57)
 Implanted defibrillator 35 (42) 23 (35)
 Biventricular pacemaker 31 (37) 28 (42)
Clinical Characteristics
Heart failure hospitalizations in past year, no. (%) 114 (64) 120 (66)
Left ventricular ejection fraction – no. (%) 30 (20, 45) 35 (21, 50)
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Baseline Characteristics Usual care alone (N=178) High-dose spironolactone (N=182)
Proportion with ejection fraction <45% – no (%) 140 (79) 123 (69)
Ischemic etiology - no. (%) 117 (66) 109 (60)
Systolic blood pressure - mmHg 123 (108, 138) 120 (106, 138)
Heart rate per minute 80 (70, 94) 78 (70, 90)
Body mass index kg/m2b 32 (27, 38) 30 (25, 35)
Jugular venous pulse ≥10 cm - no. (%) 126 (74) 135 (76)
Rales - no. (%) 99 (56) 112 (62)
Edema - no. (%) 142 (80) 139 (77)
Orth0pnea - no. (%) 154 (87) 151 (85)
New York Heart Association Class III or IV - no. (%) 153 (86) 149 (85)
Fatigue frequent or continuous – no (%) 151 (86) 156 (86)
Dyspnea frequent or continuous – no (%) 151 (86) 150 (83)
Dyspnea – visual analog scale 65 (40, 75) 60 (45, 75)
Laboratory Values
Sodium - mEq/L 140 (138, 142) 140 (138, 142)
Potassium - mEq/L 4.0 (3.6, 4.3) 3.9 (3.6, 4.3)
Blood urea nitrogen - mg/dL 22 (17, 31) 23 (16, 33)
Creatinine - mg/dL 1.3 (1.0, 1.5) 1.2 (1.0, 1.5)
Glomerular filtration rate - ml/min/1.73 m2 55 (46, 71) 58 (45, 75)
B-type natriuretic peptide, pg/ml (N=156)c 1055 (502, 1581) 1131 (680, 1986)
N-terminal pro B-type natriuretic peptide, pg/ml (N=204)c 4176 (1936, 7456) (2472, 10048)
Values shown are median (25th, 75th) or count (%)
aAt the time of randomization
bp<0.05
cSite-based qualifying values
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Table 2
Primary and Secondary Outcomes
Outcomes Usual care Alone High dose spironolactone P
Primary endpoint
Log N-terminal pro B-type natriuretic peptide
Baseline 8.23 (7.58, 8.94) 8.43 (7.90, 9.17)
96 hours (or earlier discharge) – with multiple imputation for missing values 7.64 (6.93, 8.45) 7.89 (7.19, 8.68)
Change - with multiple imputation for missing values −0.49 (−0.98, −0.14) −0.55 (−0.92, −0.18) 0.57
96 hours (or earlier discharge) – no imputation, complete cases only 7.55 (6.91, 8.31) 7.81 (7.06, 8.59)
Change - with multiple imputation for missing values −0.50 (−0.99, −0.14) −0.56 (−0.96, −0.19) 0.57
Secondary endpoints
N-terminal pro B-type natriuretic peptide, pg/ml
Baseline 3753 (1968, 7633) 4601 (2697, 9596)
96 hours (or earlier discharge) – with multiple imputation for missing values 2080 (1025, 4675) 2672 (1326, 5896)
Change - with multiple imputation for missing values −1072 (−3182, −231) −1796 (−3883, −571) 0.76
96 hours (or earlier discharge) – no imputation, complete cases only 1898 (1003, 4046) 2461 (1168, 5366)
Change - with multiple imputation for missing values −1060 (−2856, −238) −1774 (−3763, −586) 0.61
Clinical congestion score
Baseline 11 (9, 12) 10 (9, 12)
96 hours (or earlier discharge) 4 (2, 6) 4 (2, 7)
Change −6 (−8, −4) −6 (−8, −4) 0.41
Dyspnea
Likert Score (96 hours or earlier discharge) 2 (1, 3) 2 (1, 3) 0.31
Visual Analog Scale
 Baseline 65 (40, 75) 60 (45, 75)
 96 hours (or earlier discharge) 83 (70, 90) 80 (65, 90)
 Change 15 (5, 30) 15 (2, 30) 0.61
Net urine output, ml (cumulative)
 24 h 1183 (510, 1955) 1100 (483, 2131) 0.76
 48 h 2282 (1155, 4135) 2484 (1203, 4411) 0.44
 72 h 3810 (2011, 5565) 4171 (2053, 6040) 0.53
 96 h 5584 (2924, 8132) 6086 (2780, 8420) 0.57
Weight change, Ibs
 Baseline 207.1 (171.0, 250.4) 195.0 (162.6, 237.0)
 96 hours (or earlier discharge) 198.9 (167.6, 243.6) 185.1 (158.5, 230.8)
 Change −6.1 (−11.2, −1.8) −7.3 (−13.0, −2.0) 0.33
Furosemide equivalent diuretic dose, mg
Baseline 160 (120, 320) 160 (100, 320)
96 hours (or earlier discharge) 80 (40, 240) 80.0 (40, 200)
Change −80 (−160, 0.0) −80.0 (−160, 0) 0.77
Worsening heart failure, N (%)
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Outcomes Usual care Alone High dose spironolactone P
Inpatient 31 (18) 33 (19) 0.76
Outpatient (through day 30) 17 (10) 19 (11) 0.76
Values shown are median (25th, 75th) or count (%).
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